Patent Application
20240374726
This application claims priority to Taiwan Application Serial Number 112117199, filed May 9, 2023, which is herein incorporated by reference.
A sequence listing XML submitted as an xml file via EFS-WEB is incorporated herein by reference. The sequence listing XML file submitted via EFS-WEB with the name “CP-4878-US_SEQ_LIST” was created on Mar. 26, 2024, which is 31,500 bytes in size.
The present disclosure relates to a pharmaceutical product including an antigen or an antibody. More particularly, the present disclosure relates to a chimeric antigen receptor, a nucleic acid encoding the chimeric antigen receptor, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell.
Cancer, also known as malignancy, is a state of abnormal proliferation of cells, and these proliferating cells may invade other parts of the body as a disease caused by a malfunction in the control of cell division and proliferation. The number of people suffering from cancer worldwide has a growing trend. Cancer is one of the top ten causes of death for the Chinese people and has been the top ten causes of death for twenty-seven consecutive years.
Conventional cancer treatments include surgery, radiation therapy, chemotherapy, and target therapy. Cancer immunotherapy is another method for treating cancer except the above methods. The immune system of the patient is activated in the cancer immunotherapy by using tumor cells or tumor antigens to induce specific cellular and humoral immune responses for enhancing the anti-cancer ability of the patient, preventing the growth, spread, and recurrence of tumors, and achieving the purpose of removing or controlling tumors.
There are three main directions for the cancer immunotherapy: the tumor vaccine, the cell therapy and the immune checkpoint inhibitor. The chimeric antigen receptor immune cell technology is one of the cell therapy developing very rapidly in recent years. In conventional technology, the chimeric antigen receptor immune cell transfects a chimeric protein, which couples the antigen binding portion having capable of recognizing a certain tumor antigen of the antibody to the intracellular portion of the CD3-δ chain or FcεRIγ in vitro, into the immune cell by a transduction method to express the chimeric antigen receptor. The chimeric antigen receptor immune cell technology has a significant therapeutic effect in the treatment of acute leukemia and non-Hodgkin's lymphoma, and it is considered to be one of the most promising treatments for cancer. However, the cell therapy of the chimeric antigen receptor immune cell currently has the following disadvantages: lack of unique tumor-associated antigens, low efficiency of homing of immune cells to tumor sites, and inability to overcome the immunosuppressive microenvironment of solid tumors. Accordingly, the efficacy of the chimeric antigen receptor immune cell in solid tumors is greatly limited.
According to one aspect of the present disclosure, a BAG6 specific chimeric antigen receptor specific to BCL2 associated athanogene 6 (BAG6) includes, in order from an N-terminus to a C-terminus, a BAG6 antigen recognition domain, a transmembrane domain and a cytoplasmic domain. The BAG6 antigen recognition domain includes a monoclonal antibody fragment specific to BAG6, and the BAG6 antigen recognition domain includes the amino acid sequence of SEQ ID NO: 1.
According to another aspect of the present disclosure, a nucleic acid encoding the aforementioned BAG6 specific chimeric antigen receptor includes, in order from a 5′ end to a 3′ end, a BAG6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 13, a transmembrane domain coding fragment and a cytoplasmic domain coding fragment.
According to still another aspect of the present disclosure, a BAG6 specific chimeric antigen receptor expression plasmid includes, in order from a 5′ end to a 3′ end, a promoter including the nucleic acid sequence of SEQ ID NO: 25 and the aforementioned nucleic acid.
According to yet another aspect of the present disclosure, a BAG6 specific chimeric antigen receptor expressing cell includes an immune cell and the aforementioned BAG6 specific chimeric antigen receptor expression plasmid.
According to further another aspect of the present disclosure, a pharmaceutical composition for treating cancer includes the aforementioned BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
According to still another aspect of the present disclosure, a method for inhibiting a proliferation of a tumor cell includes administering a composition including a plurality of the aforementioned BAG6 specific chimeric antigen receptor expressing cells to a subject in need for a treatment of a tumor.
The present disclosure can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows:
A BAG6 specific chimeric antigen receptor, a nucleic acid encoding the BAG6 specific chimeric antigen receptor, a BAG6 specific chimeric antigen receptor expression plasmid including the nucleic acid, a BAG6 specific chimeric antigen receptor expressing cell including the BAG6 specific chimeric antigen receptor expression plasmid, a use thereof, and a pharmaceutical composition for treating cancer including the BAG6 specific chimeric antigen receptor expressing cell are provided.
Reference is made to
The transmembrane domain 130 of the BAG6 specific chimeric antigen receptor 100 can be a CD28 transmembrane domain including the amino acid sequence of SEQ ID NO: 4, a CD8 transmembrane domain including the amino acid sequence of SEQ ID NO: 5 or a KIR transmembrane domain including the amino acid sequence of SEQ ID NO: 6. The cytoplasmic domain 140 can be a IL2 receptor β chain signaling domain including the amino acid sequence of SEQ ID NO: 7, a modified CD3ζ signaling domain including the amino acid sequence of SEQ ID NO: 8, a DAP12 signaling domain including the amino acid sequence of SEQ ID NO: 9, a CD3ζ signaling domain including the amino acid sequence of SEQ ID NO: 10, a 4-1BB signaling domain including the amino acid sequence of SEQ ID NO: 11 or a combination thereof. The BAG6 specific chimeric antigen receptor 100 can further include a suicide protein including the amino acid sequence of SEQ ID NO: 12, wherein the suicide protein is linked to the C-terminus of the cytoplasmic domain 140.
According to another aspect of the present disclosure, a nucleic acid encodes the aforementioned BAG6 specific chimeric antigen receptor 100. The nucleic acid includes, in order from a 5′ end to a 3′ end, a BAG6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 13, a transmembrane domain coding fragment and a cytoplasmic domain coding fragment. The nucleic acid can further include a HLA-G antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 14, wherein the HLA-G antigen recognition domain coding fragment is linked to the 3′ end of the BAG6 antigen recognition domain coding fragment. In addition, the nucleic acid can further include a B7-H6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 15, wherein the B7-H6 antigen recognition domain is linked to the 3′ end of the BAG6 antigen recognition domain coding fragment.
The transmembrane domain coding fragment can be a CD28 transmembrane domain coding fragment including the nucleic acid sequence of SEQ ID NO: 16, a CD8 transmembrane domain coding fragment including the nucleic acid sequence of SEQ ID NO: 17 or a KIR transmembrane domain coding fragment including the nucleic acid sequence of SEQ ID NO: 18. The cytoplasmic domain coding fragment can be a IL2 receptor β chain signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 19, a modified CD3ζ signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 20, a DAP12 signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 21, a CD3ζ signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 22, a 4-1BB signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 23 or a combination thereof. In addition, the nucleic acid can further include the nucleic acid sequence of SEQ ID NO: 24, wherein the suicide gene is linked to the 3′ end of the cytoplasmic domain coding fragment.
According to still another aspect of the present disclosure, a BAG6 specific chimeric antigen receptor expression plasmid includes, in order from a 5′ end to a 3′ end, a promoter including the nucleic acid sequence of SEQ ID NO: 25 and the aforementioned nucleic acid. In addition, the BAG6 specific chimeric antigen receptor expression plasmid can further include a suicide gene including the nucleic acid sequence of SEQ ID NO: 24, wherein the suicide gene is linked to the 3′ end of the nucleic acid.
According to yet another aspect of the present disclosure, a BAG6 specific chimeric antigen receptor expressing cell includes an immune cell and the aforementioned BAG6 specific chimeric antigen receptor expression plasmid. The immune cell can be a T lymphocyte or a natural killer (NK) cell.
According to further another aspect of the present disclosure, a pharmaceutical composition for treating cancer includes the aforementioned BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier. The pharmaceutical composition for treating cancer can further include a chemotherapy drug. Preferably, the chemotherapy drug can be doxorubicin, temozolomide, gemcitabine or carboplatin.
According to still another aspect of the present disclosure, a method for inhibiting a proliferation of a tumor cell includes administering a composition including a plurality of the aforementioned BAG6 specific chimeric antigen receptor expressing cells to a subject in need for a treatment of a tumor. The tumor cell can be a breast cancer cell, a glioblastoma multiforme cell, a pancreatic cancer cell or an ovarian cancer cell.
A tumor cell specific binding ability of the BAG6 specific chimeric antigen receptor of the present disclosure, especially a specific binding ability to BAG6 expressed on the cell membrane of tumor cells, is confirmed by in vitro cell assay of the tumor cells. Accordingly, the BAG6 specific chimeric antigen receptor expressing cell of the present disclosure, which expresses the BAG6 specific chimeric antigen receptor of the present disclosure, can specifically target the tumor cells to avoid the off-target effect, thereby effectively killing the tumor cells. Therefore, the BAG6 specific chimeric antigen receptor expressing cell can be used for inhibiting the proliferation of the tumor cells in the subject in need for the treatment of the tumor. The pharmaceutical composition for treating cancer of the present disclosure includes the BAG6 specific chimeric antigen receptor expressing cell of the present disclosure, and can further include a chemotherapy drug, which can effectively kill tumor cells and thereby treat cancer.
Reference will now be made in detail to the present embodiments of the present disclosure, examples of which are illustrated in the accompanying drawings.
To explore whether treatment with the chemotherapy drug affects the expression of BAG6, HLA-G and B7-H6 on the cell membrane of tumor cells, the tumor cells used were human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG-05MG (hereinafter referred to as DBTRG), human pancreatic cancer cell line AsPC-1, and human ovarian cancer cell line SKOV3. The tumor cells used were all purchased from the American Type Culture Collection (ATCC). The human breast cancer cell line MDA-MB-231 is a triple-negative breast cancer cell line, that is, the hormone receptor (ER, PR) and HER-2 receptor thereof are negative, and the human breast cancer cell line MDA-MB-231 was cultured in RPMI culture medium including 10% fetal bovine serum (FBS). The human malignant brain tumor cell line DBTRG was cultured in DMEM culture medium including 10% FBS. The human pancreatic cancer cell line AsPC-1 was cultured in RPMI culture medium including 10% FBS. The human ovarian cancer cell line SKOV3 was cultured in McCoy's 5A culture medium including 10% FBS.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 6-well plate at a density of 2×105 cells/well. The cells were subsequently incubated for 24 hours. Each type of the tumor cells was divided into two groups. In a control, the tumor cells were untreated. In a chemotherapy group, the tumor cells were treated with the chemotherapy drug for 48 hours. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). Then, the expression of BAG6 of the tumor cells of each group were detected by immunofluorescence staining assay, and the expression of BAG6, HLA-G and B7-H6 of the tumor cells of each group were detected by the flow cytometry.
Reference is made to
As shown by the results of
Reference is made to
Reference is made to
A BAG6 specific chimeric antigen receptor of 1st embodiment includes, in order from an N-terminus to a C-terminus, the BAG6 antigen recognition domain including the amino acid sequence of SEQ ID NO: 1, the CD28 transmembrane domain including the amino acid sequence of SEQ ID NO: 4, the IL2 receptor β chain signaling domain including the amino acid sequence of SEQ ID NO: 7, and the modified CD3ζ signaling domain including the amino acid sequence of SEQ ID NO: 8. A nucleic acid of 1st embodiment includes, in order from a 5′ end to a 3′ end, the BAG6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 13, the CD28 transmembrane domain coding fragment including the nucleic acid sequence of SEQ ID NO: 16, the IL2 receptor β chain signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 19, and the modified CD3ζ signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 20.
Reference is made to
Reference is made to
The BAG6 specific chimeric antigen receptor of 1st embodiment was transduced into the primary T lymphocyte to obtain a BAG6 specific chimeric antigen receptor expressing cell of Example 1 of the present disclosure (hereinafter referred to as Example 1). The effects of Example 1 and the pharmaceutical composition for treating cancer including Example 1 of the present disclosure on inducing the death of the breast cancer cells, the glioblastoma multiforme cells, the pancreatic cancer cells, and the ovarian cancer cells were further demonstrated in following experiments.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells/well. The cells were subsequently incubated for 48 hours. Each type of the tumor cells was divided into six groups. In a control, the tumor cells were untreated. In a group 1, the tumor cells were treated with the chemotherapy drug. In a group 2, the tumor cells were treated with the parental primary T lymphocyte. In a group 3, the tumor cells are treated with the parental primary T lymphocyte and the chemotherapy drug. In a group 4, the tumor cells were treated with Example 1. In a group 5, the tumor cells were treated with Example 1 and the chemotherapy drug. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). In the group 4 and the group 5, the number of Example 1 treated was 1×105 cells. In the group 2 and the group 3, the number of the parental primary T lymphocyte treated was 1×105 cells. The treated cells of each group were stained with Annexin V-FITC and propidium iodide (PI), and the apoptosis and the death of the tumor cells were detected by the flow cytometry. The sum of the percentage of cells stained with Annexin V-FITC and/or PI were calculated to obtain the cytotoxicity. The results of the cytotoxicity were counted after three independent trials in each group.
Reference is made to
The results of Table 1,
The results of Table 1,
The results of Table 1,
The results of Table 1,
The BAG6 specific chimeric antigen receptor of 1st embodiment was transduced into the primary NK cell to obtain a BAG6 specific chimeric antigen receptor expressing cell of Example 2 of the present disclosure (hereinafter referred to as Example 2). The effects of Example 2 and the pharmaceutical composition for treating cancer including Example 2 of the present disclosure on inducing the death of the breast cancer cells, the glioblastoma multiforme cells, the pancreatic cancer cells, and the ovarian cancer cells were further demonstrated in following experiments.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells/well. The cells were subsequently incubated for 48 hours. Each type of the tumor cells was divided into six groups. In a control, the tumor cells were untreated. In a group 1, the tumor cells were treated with the chemotherapy drug. In a group 2, the tumor cells were treated with the parental primary NK cell. In a group 3, the tumor cells were treated with the parental primary NK cell and the chemotherapy drug. In a group 4, the tumor cells were treated with Example 2. In a group 5, the tumor cells were treated with Example 2 and the chemotherapy drug. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). In the group 4 and the group 5, the number of Example 2 treated was 1×105 cells. In the group 2 and the group 3, the number of the parental primary NK cell treated was 1×105 cells. The treated cells of each group were stained with Annexin V-FITC and PI, and the apoptosis and the death of the tumor cells were detected by the flow cytometry. The sum of the percentage of cells stained with Annexin V-FITC and/or PI were calculated to obtain the cytotoxicity. The results of the cytotoxicity were counted after three independent trials in each group.
Reference is made to
The results of Table 2,
The results of Table 2,
The results of Table 2,
The results of Table 2,
The results of Table 1, Table 2 and
A BAG6 specific chimeric antigen receptor of 2nd embodiment includes, in order from an N-terminus to a C-terminus, the BAG6 antigen recognition domain including the amino acid sequence of SEQ ID NO: 1, the HLA-G antigen recognition domain including the amino acid sequence of SEQ ID NO: 2, the KIR transmembrane domain including the amino acid sequence of SEQ ID NO: 6, and the DAP12 signaling domain including the amino acid sequence of SEQ ID NO: 9. In addition, the BAG6 specific chimeric antigen receptor of 2nd embodiment further includes the suicide protein including the amino acid sequence of SEQ ID NO: 12, which is linked to the C-terminus of the DAP12 signaling domain. A nucleic acid of 2nd embodiment includes, in order from a 5′ end to a 3′ end, the BAG6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 13, the HLA-G antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 14, the KIR transmembrane domain coding fragment including the nucleic acid sequence of SEQ ID NO: 18, and the DAP12 signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 21. In addition, the nucleic acid of 2nd embodiment further includes the suicide gene including the nucleic acid sequence of SEQ ID NO: 24, which is linked to the 3′ end of the DAP12 signaling domain coding fragment.
Reference is made to
Reference is made to
The BAG6 specific chimeric antigen receptor of 2nd embodiment was transduced into the primary T lymphocyte to obtain a BAG6 specific chimeric antigen receptor expressing cell of Example 3 of the present disclosure (hereinafter referred to as Example 3). The effects of Example 3 and the pharmaceutical composition for treating cancer including Example 3 of the present disclosure on inducing the death of the breast cancer cells, the glioblastoma multiforme cells, the pancreatic cancer cells, and the ovarian cancer cells were further demonstrated in following experiments.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells/well. The cells were subsequently incubated for 48 hours. Each type of the tumor cells was divided into six groups. In a control, the tumor cells were untreated. In a group 1, the tumor cells were treated with the chemotherapy drug. In a group 2, the tumor cells were treated with the parental primary T lymphocyte. In a group 3, the tumor cells were treated with the parental primary T lymphocyte and the chemotherapy drug. In a group 4, the tumor cells were treated with Example 3. In a group 5, the tumor cells were treated with Example 3 and the chemotherapy drug. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). In the group 4 and the group 5, the number of Example 3 treated was 1×105 cells. In the group 2 and the group 3, the number of the parental primary T lymphocyte treated was 1×105 cells. The treated cells of each group were stained with Annexin V-FITC and PI, and the apoptosis and the death of the tumor cells were detected by the flow cytometry. The sum of the percentage of cells stained with Annexin V-FITC and/or PI were calculated to obtain the cytotoxicity. The results of the cytotoxicity were counted after three independent trials in each group.
Reference is made to
The results of Table 3,
The results of Table 3,
The results of Table 3,
The results of Table 3,
The BAG6 specific chimeric antigen receptor of 2nd embodiment was transduced into the primary NK cell to obtain a BAG6 specific chimeric antigen receptor expressing cell of Example 4 of the present disclosure (hereinafter referred to as Example 4). The effects of Example 4 and the pharmaceutical composition for treating cancer including Example 4 of the present disclosure on inducing the death of the breast cancer cells, the glioblastoma multiforme cells, the pancreatic cancer cells, and the ovarian cancer cells were further demonstrated in following experiments.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells/well. The cells were subsequently incubated for 48 hours. Each type of the tumor cells was divided into six groups. In a control, the tumor cells were untreated. In a group 1, the tumor cells were treated with the chemotherapy drug. In a group 2, the tumor cells were treated with the parental primary NK cell. In a group 3, the tumor cells were treated with the parental primary NK cell and the chemotherapy drug. In a group 4, the tumor cells were treated with Example 4. In a group 5, the tumor cells were treated with Example 4 and the chemotherapy drug. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). In the group 4 and the group 5, the number of Example 4 treated was 1×105 cells. In the group 2 and the group 3, the number of the parental primary NK cell treated was 1×105 cells. The treated cells of each group were stained with Annexin V-FITC and PI, and the apoptosis and the death of the tumor cells were detected by the flow cytometry. The sum of the percentage of cells stained with Annexin V-FITC and/or PI were calculated to obtain the cytotoxicity. The results of the cytotoxicity were counted after three independent trials in each group.
Reference is made to
The results of Table 4,
The results of Table 4,
The results of Table 4,
The results of Table 4,
The results of Table 3, Table 4 and
A BAG6 specific chimeric antigen receptor of 3rd embodiment includes, in order from an N-terminus to a C-terminus, the BAG6 antigen recognition domain including the amino acid sequence of SEQ ID NO: 1, the B7-H6 antigen recognition domain including the amino acid sequence of SEQ ID NO: 3, the CD8 transmembrane domain including the amino acid sequence of SEQ ID NO: 5, the 4-1BB signaling domain including the amino acid sequence of SEQ ID NO: 11, and the CD3ζ signaling domain including the amino acid sequence of SEQ ID NO: 10. In addition, the BAG6 specific chimeric antigen receptor of 3rd embodiment further includes the suicide protein including the amino acid sequence of SEQ ID NO: 12, which is linked to the C-terminus of the CD3ζ signaling domain. A nucleic acid of 3rd embodiment includes, in order from a 5′ end to a 3′ end, the BAG6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 13, the B7-H6 antigen recognition domain coding fragment including the nucleic acid sequence of SEQ ID NO: 15, the CD8 transmembrane domain coding fragment including the nucleic acid sequence of SEQ ID NO: 17, the 4-1BB signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 23, and the CD3ζ signaling domain coding fragment including the nucleic acid sequence of SEQ ID NO: 22. In addition, the nucleic acid of 3rd embodiment further includes the suicide gene including the nucleic acid sequence of SEQ ID NO: 24, which is linked to the 3′ end of the CD3ζ signaling domain coding fragment.
Reference is made to
Reference is made to
The BAG6 specific chimeric antigen receptor of 3rd embodiment was transduced into the primary T lymphocyte to obtain a BAG6 specific chimeric antigen receptor expressing cell of Example 5 of the present disclosure (hereinafter referred to as Example 5). The effects of Example 5 and the pharmaceutical composition for treating cancer including Example 5 of the present disclosure on inducing the death of the breast cancer cells, the glioblastoma multiforme cells, the pancreatic cancer cells, and the ovarian cancer cells were further demonstrated in following experiments.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells/well. The cells were subsequently incubated for 48 hours. Each type of the tumor cells was divided into six groups. In a control, the tumor cells were untreated. In a group 1, the tumor cells were treated with the chemotherapy drug. In a group 2, the tumor cells were treated with the parental primary T lymphocyte. In a group 3, the tumor cells were treated with the parental primary T lymphocyte and the chemotherapy drug. In a group 4, the tumor cells were treated with Example 5. In a group 5, the tumor cells were treated with Example 5 and the chemotherapy drug. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). In the group 4 and the group 5, the number of Example 5 treated was 1×105 cells. In the group 2 and the group 3, the number of the parental primary T lymphocyte treated was 1×105 cells. The treated cells of each group were stained with Annexin V-FITC and PI, and the apoptosis and the death of the tumor cells were detected by the flow cytometry. The sum of the percentage of cells stained with Annexin V-FITC and/or PI were calculated to obtain the cytotoxicity. The results of the cytotoxicity were counted after three independent trials in each group.
Reference is made to
The results of Table 5,
The results of Table 5,
The results of Table 5,
The results of Table 5,
The BAG6 specific chimeric antigen receptor of 3rd embodiment was transduced into the primary NK cell to obtain a BAG6 specific chimeric antigen receptor expressing cell of Example 6 of the present disclosure (hereinafter referred to as Example 6). The effects of Example 6 and the pharmaceutical composition for treating cancer including Example 6 of the present disclosure on inducing the death of the breast cancer cells, the glioblastoma multiforme cells, the pancreatic cancer cells, and the ovarian cancer cells were further demonstrated in following experiments.
First, the human breast cancer cell line MDA-MB-231, the human malignant brain tumor cell line DBTRG, the human pancreatic cancer cell line AsPC-1 and the human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells/well. The cells were subsequently incubated for 48 hours. Each type of the tumor cells was divided into six groups. In a control, the tumor cells were untreated. In a group 1, the tumor cells were treated with the chemotherapy drug. In a group 2, the tumor cells were treated with the parental primary NK cell. In a group 3, the tumor cells were treated with the parental primary NK cell and the chemotherapy drug. In a group 4, the tumor cells were treated with Example 6. In a group 5, the tumor cells were treated with Example 6 and the chemotherapy drug. The chemotherapy drug used for treating the human breast cancer cell line MDA-MB-231 was doxorubicin (200 nM), the chemotherapy drug used for treating the human malignant brain tumor cell line DBTRG was temozolomide (80 μg/mL), the chemotherapy drug used for treating the human pancreatic cancer cell line AsPC-1 was gemcitabine (20 μM), and the chemotherapy drug used for treating the human ovarian cancer cell line SKOV3 was carboplatin (20 μM). In the group 4 and the group 5, the number of Example 6 treated was 1×105 cells. In the group 2 and the group 3, the number of the parental primary NK cell treated was 1×105 cells. The treated cells of each group were stained with Annexin V-FITC and PI, and the apoptosis and the death of the tumor cells were detected by the flow cytometry. The sum of the percentage of cells stained with Annexin V-FITC and/or PI were calculated to obtain the cytotoxicity. The results of the cytotoxicity were counted after three independent trials in each group.
Reference is made to
The results of Table 6,
The results of Table 6,
The results of Table 6,
The results of Table 6,
The results of Table 5, Table 6 and
To sum up, the BAG6 specific chimeric antigen receptor of the present disclosure has excellent specific binding ability to the tumor cells, in particular, specific binding to BAG6 expressed on the cell membrane of the tumor cells. Accordingly, the BAG6 specific chimeric antigen receptor expressing cell of the present disclosure, which expresses the BAG6 specific chimeric antigen receptor of the present disclosure, can specifically target the tumor cells to avoid the off-target effect, thereby effectively killing the tumor cells. Therefore, the BAG6 specific chimeric antigen receptor expressing cell can be used for inhibiting the proliferation of the tumor cells in the subject in need for the treatment of the tumor. The pharmaceutical composition for treating cancer includes the BAG6 specific chimeric antigen receptor expressing cell of the present disclosure and the pharmaceutically acceptable carrier, which can effectively kill the tumor cells and thereby treat cancer. The pharmaceutical composition for treating cancer further including the chemotherapy drug can increase the BAG6 expression level on the plasma membrane of the tumor cells, thereby enhancing the killing effect of the BAG6 specific chimeric antigen receptor expressing cell on the tumor cells. Accordingly, the pharmaceutical composition for treating cancer further including the chemotherapy drug has more excellent tumor cell toxicity.
Although the present disclosure has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
It will be apparent to those skilled in the art that various modifications and variations can be made to the structure of the present disclosure without departing from the scope or spirit of the disclosure. In view of the foregoing, it is intended that the present disclosure cover modifications and variations of this disclosure provided they fall within the scope of the following claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 112117199 | May 2023 | TW | national |
